Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview
| Autor: | Ioana Maria Lambrescu, Viola Barucca, Nicola Fazio, Diana Martins |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Everolimus business.industry Health Policy Phases of clinical research Cancer Pharmacology Neuroendocrine tumors medicine.disease Discontinuation 03 medical and health sciences 0302 clinical medicine Breast cancer Renal cell carcinoma 030220 oncology & carcinogenesis Internal medicine medicine Pharmacology (medical) 030212 general & internal medicine Adverse effect business Pharmacology Toxicology and Pharmaceutics (miscellaneous) medicine.drug |
| Zdroj: | Expert Opinion on Orphan Drugs. 5:525-536 |
| ISSN: | 2167-8707 |
| DOI: | 10.1080/21678707.2017.1334550 |
| Popis: | Introduction: Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), is approved as an anti-tumor therapy, as single agent or in combination, for advanced neuroendocrine tumors (NETs), breast and renal carcinomas.Areas covered: In this review we analyzed some general features of everolimus toxicity profile and evidence data about its adverse events (AEs) coming from the most relevant phase III clinical trials. Furthermore we critically discuss this by comparing the different clinical areas of neuroendocrine, breast and kidney malignancies and addressing the clinical management of the everolimus toxicity. Most of the AEs related to everolimus are mild to moderate and manageable with dose reduction or temporary interruptions of therapy. However, a few severe AEs can lead to definitive discontinuation of therapy. Therefore clinicians employing this therapy regardless of tumor type should provide patients with prevention and management strategies in order to increase treatment adherence and... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|